April 11, 2018

Selexis SA Strengthens Cell Line Development Services for Partners with Key Strategic Hires and Investment in State-of-the-Art Laboratory Equipment

Read More
March 07, 2018

Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics

Read More
February 26, 2018

Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

Read More

Media Downloads